Voyager Therapeutics (VYGR) Competitors

$3.09 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$3.16 +0.06 (+2.10%)

As of 07:35 AM Eastern

VYGR vs. SLN, NVCT, ANNX, DBVT, and ACRS

Should you buy Voyager Therapeutics stock or one of its competitors? Voyager Therapeutics's main competitors and comparable companies include Silence Therapeutics (SLN), Nuvectis Pharma (NVCT), Annexon (ANNX), DBV Technologies (DBVT), and Aclaris Therapeutics (ACRS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Voyager Therapeutics compare to Silence Therapeutics?

Silence Therapeutics (NASDAQ:SLN) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Silence Therapeutics has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market. Comparatively, Voyager Therapeutics has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market.

Silence Therapeutics presently has a consensus price target of $53.50, suggesting a potential upside of 338.52%. Voyager Therapeutics has a consensus price target of $16.50, suggesting a potential upside of 433.98%. Given Voyager Therapeutics' higher possible upside, analysts clearly believe Voyager Therapeutics is more favorable than Silence Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Silence Therapeutics has higher earnings, but lower revenue than Voyager Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$615K	1,194.39	-$88.61M	-$1.28	N/A
Voyager Therapeutics	$40.37M	4.72	-$119.72M	-$1.80	N/A

Voyager Therapeutics has a net margin of -312.63% compared to Silence Therapeutics' net margin of -8,943.86%. Voyager Therapeutics' return on equity of -57.92% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-8,943.86%	-106.94%	-47.99%
Voyager Therapeutics	-312.63%	-57.92%	-45.00%

98.7% of Silence Therapeutics shares are held by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are held by institutional investors. 3.0% of Silence Therapeutics shares are held by insiders. Comparatively, 12.7% of Voyager Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Silence Therapeutics had 3 more articles in the media than Voyager Therapeutics. MarketBeat recorded 3 mentions for Silence Therapeutics and 0 mentions for Voyager Therapeutics. Silence Therapeutics' average media sentiment score of 0.00 equaled Voyager Therapeutics'average media sentiment score.

Company	Overall Sentiment
Silence Therapeutics	Neutral
Voyager Therapeutics	Neutral

Summary

Silence Therapeutics beats Voyager Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Voyager Therapeutics compare to Nuvectis Pharma?

Voyager Therapeutics (NASDAQ:VYGR) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

Voyager Therapeutics currently has a consensus target price of $16.50, indicating a potential upside of 433.98%. Nuvectis Pharma has a consensus target price of $36.25, indicating a potential upside of 64.77%. Given Voyager Therapeutics' higher possible upside, equities research analysts clearly believe Voyager Therapeutics is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Nuvectis Pharma has lower revenue, but higher earnings than Voyager Therapeutics. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$40.37M	4.72	-$119.72M	-$1.80	N/A
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A

48.0% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are owned by institutional investors. 12.7% of Voyager Therapeutics shares are owned by company insiders. Comparatively, 28.6% of Nuvectis Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Nuvectis Pharma has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -312.63%. Voyager Therapeutics' return on equity of -57.92% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-312.63%	-57.92%	-45.00%
Nuvectis Pharma	N/A	-184.25%	-105.24%

Voyager Therapeutics has a beta of 1.32, meaning that its share price is 32% more volatile than the broader market. Comparatively, Nuvectis Pharma has a beta of -0.26, meaning that its share price is 126% less volatile than the broader market.

In the previous week, Nuvectis Pharma had 2 more articles in the media than Voyager Therapeutics. MarketBeat recorded 2 mentions for Nuvectis Pharma and 0 mentions for Voyager Therapeutics. Nuvectis Pharma's average media sentiment score of 0.08 beat Voyager Therapeutics' score of 0.00 indicating that Nuvectis Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Voyager Therapeutics	Neutral
Nuvectis Pharma	Neutral

Summary

Nuvectis Pharma beats Voyager Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Voyager Therapeutics compare to Annexon?

Voyager Therapeutics (NASDAQ:VYGR) and Annexon (NASDAQ:ANNX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

48.0% of Voyager Therapeutics shares are owned by institutional investors. 12.7% of Voyager Therapeutics shares are owned by company insiders. Comparatively, 10.3% of Annexon shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Annexon has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -312.63%. Voyager Therapeutics' return on equity of -57.92% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-312.63%	-57.92%	-45.00%
Annexon	N/A	-106.15%	-79.82%

Voyager Therapeutics presently has a consensus target price of $16.50, indicating a potential upside of 433.98%. Annexon has a consensus target price of $15.14, indicating a potential upside of 257.99%. Given Voyager Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Voyager Therapeutics is more favorable than Annexon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Annexon	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Annexon had 2 more articles in the media than Voyager Therapeutics. MarketBeat recorded 2 mentions for Annexon and 0 mentions for Voyager Therapeutics. Annexon's average media sentiment score of 0.49 beat Voyager Therapeutics' score of 0.00 indicating that Annexon is being referred to more favorably in the news media.

Company	Overall Sentiment
Voyager Therapeutics	Neutral
Annexon	Neutral

Voyager Therapeutics has a beta of 1.32, indicating that its share price is 32% more volatile than the broader market. Comparatively, Annexon has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market.

Voyager Therapeutics has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$40.37M	4.72	-$119.72M	-$1.80	N/A
Annexon	N/A	N/A	-$206.69M	-$1.16	N/A

Summary

Voyager Therapeutics beats Annexon on 11 of the 16 factors compared between the two stocks.

How does Voyager Therapeutics compare to DBV Technologies?

DBV Technologies (NASDAQ:DBVT) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

DBV Technologies has a beta of -0.95, indicating that its share price is 195% less volatile than the broader market. Comparatively, Voyager Therapeutics has a beta of 1.32, indicating that its share price is 32% more volatile than the broader market.

Voyager Therapeutics has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	137.69	-$146.95M	-$3.51	N/A
Voyager Therapeutics	$40.37M	4.72	-$119.72M	-$1.80	N/A

Voyager Therapeutics has a net margin of -312.63% compared to DBV Technologies' net margin of -3,506.53%. Voyager Therapeutics' return on equity of -57.92% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-3,506.53%	-119.33%	-84.43%
Voyager Therapeutics	-312.63%	-57.92%	-45.00%

In the previous week, DBV Technologies had 3 more articles in the media than Voyager Therapeutics. MarketBeat recorded 3 mentions for DBV Technologies and 0 mentions for Voyager Therapeutics. DBV Technologies' average media sentiment score of 0.71 beat Voyager Therapeutics' score of 0.00 indicating that DBV Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
DBV Technologies	Positive
Voyager Therapeutics	Neutral

71.7% of DBV Technologies shares are held by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are held by institutional investors. 1.1% of DBV Technologies shares are held by insiders. Comparatively, 12.7% of Voyager Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

DBV Technologies currently has a consensus target price of $48.50, suggesting a potential upside of 292.71%. Voyager Therapeutics has a consensus target price of $16.50, suggesting a potential upside of 433.98%. Given Voyager Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Voyager Therapeutics is more favorable than DBV Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Voyager Therapeutics beats DBV Technologies on 12 of the 17 factors compared between the two stocks.

How does Voyager Therapeutics compare to Aclaris Therapeutics?

Aclaris Therapeutics (NASDAQ:ACRS) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

Aclaris Therapeutics has higher earnings, but lower revenue than Voyager Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	98.21	-$64.92M	-$0.58	N/A
Voyager Therapeutics	$40.37M	4.72	-$119.72M	-$1.80	N/A

Aclaris Therapeutics has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market. Comparatively, Voyager Therapeutics has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market.

98.3% of Aclaris Therapeutics shares are held by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are held by institutional investors. 4.8% of Aclaris Therapeutics shares are held by company insiders. Comparatively, 12.7% of Voyager Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Voyager Therapeutics has a net margin of -312.63% compared to Aclaris Therapeutics' net margin of -921.50%. Voyager Therapeutics' return on equity of -57.92% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%
Voyager Therapeutics	-312.63%	-57.92%	-45.00%

Aclaris Therapeutics presently has a consensus price target of $11.33, suggesting a potential upside of 106.06%. Voyager Therapeutics has a consensus price target of $16.50, suggesting a potential upside of 433.98%. Given Voyager Therapeutics' higher possible upside, analysts clearly believe Voyager Therapeutics is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Aclaris Therapeutics had 2 more articles in the media than Voyager Therapeutics. MarketBeat recorded 2 mentions for Aclaris Therapeutics and 0 mentions for Voyager Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.33 beat Voyager Therapeutics' score of 0.00 indicating that Aclaris Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aclaris Therapeutics	Neutral
Voyager Therapeutics	Neutral

Summary

Aclaris Therapeutics beats Voyager Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Voyager Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VYGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VYGR vs. The Competition

Export

Metric	Voyager Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$190.41M	$3.89B	$7.22B	$12.94B
Dividend Yield	N/A	3.64%	2.57%	12.80%
P/E Ratio	-1.72	14.23	275.50	25.40
Price / Sales	4.72	1,443.81	649.31	81.48
Price / Cash	N/A	41.62	28.13	34.74
Price / Book	0.88	15.84	10.64	6.32
Net Income	-$119.72M	-$22.90M	$3.49B	$358.20M
7 Day Performance	-3.13%	-1.29%	-0.27%	0.42%
1 Month Performance	-8.85%	-4.48%	-2.70%	-3.30%
1 Year Performance	-27.63%	37.80%	18.14%	5.33%

Voyager Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VYGR Voyager Therapeutics	2.6318 of 5 stars	$3.09 flat	$16.50 +434.0%	-27.6%	$190.41M	$40.37M	N/A	141
SLN Silence Therapeutics	2.1489 of 5 stars	$13.06 +0.3%	$53.50 +309.6%	+149.5%	$783.92M	$615K	N/A	88	Positive News
NVCT Nuvectis Pharma	3.504 of 5 stars	$23.35 -2.7%	$36.25 +55.2%	+250.9%	$783.13M	N/A	N/A	13	Gap Down
ANNX Annexon	2.6119 of 5 stars	$3.95 +0.3%	$15.14 +283.4%	+47.9%	$746.94M	N/A	N/A	92	Gap Down
DBVT DBV Technologies	3.4381 of 5 stars	$12.35 +4.2%	$48.50 +292.7%	+30.0%	$745.10M	$5.64M	N/A	161	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VYGR) was last updated on 9/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Voyager Therapeutics (VYGR) Competitors

VYGR vs. SLN, NVCT, ANNX, DBVT, and ACRS

How does Voyager Therapeutics compare to Silence Therapeutics?

Summary

How does Voyager Therapeutics compare to Nuvectis Pharma?

Summary

How does Voyager Therapeutics compare to Annexon?

Summary

How does Voyager Therapeutics compare to DBV Technologies?

Summary

How does Voyager Therapeutics compare to Aclaris Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VYGR vs. The Competition

Voyager Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Voyager Therapeutics (VYGR) Competitors

VYGR vs. SLN, NVCT, ANNX, DBVT, and ACRS

How does Voyager Therapeutics compare to Silence Therapeutics?

Which has more volatility & risk, SLN or VYGR?

Do analysts prefer SLN or VYGR?

Which has preferable valuation & earnings, SLN or VYGR?

Is SLN or VYGR more profitable?

Do institutionals and insiders hold more shares of SLN or VYGR?

Does the media favor SLN or VYGR?

Summary

How does Voyager Therapeutics compare to Nuvectis Pharma?

Do analysts recommend VYGR or NVCT?

Which has preferable earnings & valuation, VYGR or NVCT?

Do institutionals & insiders have more ownership in VYGR or NVCT?

Is VYGR or NVCT more profitable?

Which has more risk & volatility, VYGR or NVCT?

Does the media prefer VYGR or NVCT?

Summary

How does Voyager Therapeutics compare to Annexon?

Do insiders and institutionals have more ownership in VYGR or ANNX?

Is VYGR or ANNX more profitable?

Do analysts rate VYGR or ANNX?

Does the media prefer VYGR or ANNX?

Which has more volatility & risk, VYGR or ANNX?

Which has better valuation and earnings, VYGR or ANNX?

Summary

How does Voyager Therapeutics compare to DBV Technologies?

Which has more risk and volatility, DBVT or VYGR?

Which has stronger earnings & valuation, DBVT or VYGR?

Is DBVT or VYGR more profitable?

Does the media favor DBVT or VYGR?

Do institutionals and insiders hold more shares of DBVT or VYGR?

Do analysts prefer DBVT or VYGR?

Summary

How does Voyager Therapeutics compare to Aclaris Therapeutics?

Which has better valuation & earnings, ACRS or VYGR?

Which has more volatility and risk, ACRS or VYGR?

Do insiders and institutionals hold more shares of ACRS or VYGR?

Is ACRS or VYGR more profitable?

Do analysts prefer ACRS or VYGR?

Does the media favor ACRS or VYGR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VYGR vs. The Competition

Voyager Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools